Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'
- PMID: 35853842
- DOI: 10.1002/ejhf.2622
Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease. Letter regarding the article 'Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial'
Comment in
-
Reply to 'Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease'.Eur J Heart Fail. 2022 Oct;24(10):1990-1992. doi: 10.1002/ejhf.2690. Epub 2022 Sep 28. Eur J Heart Fail. 2022. PMID: 36114731 No abstract available.
Comment on
-
Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.Eur J Heart Fail. 2022 Jul;24(7):1239-1248. doi: 10.1002/ejhf.2527. Epub 2022 Jun 6. Eur J Heart Fail. 2022. PMID: 35596935 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
